Erythropoietin as a new therapeutic opportunity in brain inflammation and neurodegenerative diseases

References

• Wojchowski DM, Gregory RC, Miller CP, et al. Signal transduction in the erythropoietin receptor system. Exp Cell Res 1999;253:143–56.
   PubMed Web of Science ®Google Scholar
• Bazan JF. Haemopoietic receptors and helical cytokines. Immunol Today 1990;11:350–354.
   PubMedGoogle Scholar
• Lappin T. The cellular biology of erythropoietin receptors. The Oncologist 2003;8(suppl 1):15–18.
   PubMed Web of Science ®Google Scholar
• Rama Bretón R, García Rodríguez JC. Excitotoxicity and oxidative stress in acute ischemic stroke. In: Garcia Rodriguez JC ed. Acute ischemic stroke, ISBN 978-953-307-983-7, InTech; 2012. Available from: http://www.intechopen.com/books/acute-ischemic-stroke/excitotoxicity-and-oxidative-stress-in-acute-ischemic-stroke
   Google Scholar
• Marti HH. Erythropoietin and the hypoxic brain. J Exp Biol 2004;207(Pt 18):3233–42.
   PubMed Web of Science ®Google Scholar
• Grasso G, Sfacteria A, Cerami A, Brines M. Erythropoietin as a tissue-protective cytokine in brain injury: what do we know and where do we go? Neuroscientist 2004;10:93–8.
   PubMed Web of Science ®Google Scholar
• Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem. 1992;59:1609–1623.
   PubMed Web of Science ®Google Scholar
• Sullivan JL. Iron and the sex difference in heart disease risk. Lancet 1981;1:1293–1294.
   PubMed Web of Science ®Google Scholar
• Bailey DM, Robach P, Thomsen JJ, Lundby C. Erythropoietin depletes iron stores: antioxidant neuroprotection for ischemic stroke? Stroke. 2006;37:2453.
   PubMed Web of Science ®Google Scholar
• Cardenas-Rodriguez N, Huerta-Gertrudis B, Rivera-Espinosa L, et al. Role of oxidative stress in refractory epilepsy: evidence in patients and experimental models. Int. J. Mol. Sci. 2013, 14, 1455–1476.
   PubMed Web of Science ®Google Scholar
• Gorter JA, Mesquita ARM, van Vliet EA, et al. Increased expression of ferritin, an iron-storage protein, in specific regions of the parahippocampal cortex of epileptic rats. Epilepsia 2005;46(9):1371–1379.
   PubMed Web of Science ®Google Scholar
• Gilgun-Sherki Y1, Melamed E, Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol. 2004;251(3):261–8.
   PubMed Web of Science ®Google Scholar
• Stephenson E, Nathoo N, Mahjoub Y, et al. Iron in multiple sclerosis: roles in neurodegeneration and repair. Nat Rev Neurol 2014;10:459–468.
   PubMed Web of Science ®Google Scholar
• Perry G, Cash AD, Smith MA. Alzheimer disease and oxidative stress. J Biomed Biotechnol 2002;2(3):120–123.
   PubMedGoogle Scholar
• Zhao Y, Zhao B. Oxidative stress and the pathogenesis of Alzheimer's disease. Hindawi Publishing Corporation. Oxidative Medicine and Cellular Longevity. 2013, Article ID 316523, 10 pages. http://dx.doi.org/10.1155/2013/316523.
   Google Scholar
• Friedlich AL, Smith MA, Zhu X, et al. Oxidative stress in Parkinson's disease. The Open Pathol J 2009;3:38–42.
   Google Scholar
• Repetto MG, Domínguez RO, Marschoff ER, Serra JA. Free radicals, oxidative stress and oxidative damage in Parkinson's disease, mechanisms in Parkinson's disease—models and treatments, Dushanova J, editor, ISBN: 978-953-307-876-2, InTech; 2012. Available from: http://www.intechopen. com/books/mechanisms-in-parkinson-s-disease-models-and-treatments/free-radicalsoxidative-stress-and-oxidative-damage-in-parkinson-s-disease
   Google Scholar
• Jeong SY, Rathore KI, Schulz K, Ponka P, Arosio P, David S. Dysregulation od iron homeostasis in the CNS contributes to disease progression in a mouse model of amyotrophic lateral sclerosis. J Neusosc 2009;29(3):610–619.
   PubMed Web of Science ®Google Scholar
• Gregory A, Hayflick SJ. Neurodegeneration with brain iron accumulation. Folia Neuropathol 2005;43(4):286–296.
   PubMedGoogle Scholar
• Gordon N. Pantothenate kinase-associated neurodegeneration (Hallervorden–Spatz syndrome). Eur J Paediatr Neurol 2002;6(5):243–7.
   PubMedGoogle Scholar
• Semenza Gl. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 2000;881474–80.
   Google Scholar
• Brown GC, Neher JJ. Inflammatory neurodegeneration and mechanisms of microglial killing of neurons. Mol Neurobiol 2010;41(2–3):242–7.
   PubMed Web of Science ®Google Scholar
• Vezzani A, French J, Bartfai T, Baram TZ. The role of inflammation in epilepsy. Nat Rev Neurol 2011;7:31–40.
   PubMed Web of Science ®Google Scholar
• Lorigados PL, Morales CLM, Orozco SS, et al. Inflammatory mediators in epilepsy. Curr Pharm Des 2013;19:6766–6772.
   PubMed Web of Science ®Google Scholar
• Friedman A, Dingledine R. Molecular cascades that mediate the influence of inflammation on epilepsy. Epilepsia 2011;52(Suppl. 3):33–39.
   PubMed Web of Science ®Google Scholar
• Chu K, Jung KH, Lee ST, et al. Erythropoietin reduces epileptogenic processes following status epilepticus. Epilepsia 2008;49(10):1723–32.
   PubMed Web of Science ®Google Scholar
• de Lemos ML, Vazquez de la Torre A, Petrova D, et al. Evaluation of hypoxia inducible factor expression in inflammatory and neurodegenerative brain models. Int J Biochem Cell Biol 2013;45:1377–1388.
   PubMed Web of Science ®Google Scholar
• Girgenti MJ, Hunsberger J, Duman CH, et al. Erythropoietin induction by electroconvulsive seizure, gene regulation, and antidepressant-like behavioral effects. Biol Psychiatry 2009;66(3):267–274.
   PubMed Web of Science ®Google Scholar
• Roesler R, Quevedo J, Schroder N. Erythropoietin, glutamate, and neuroprotection. NEJM 2004;351(14):1465–6.
   PubMed Web of Science ®Google Scholar
• Chu K, Jung KH, Lee ST, et al. Erythropoietin reduces epileptogenic processes following status epilepticus. Epilepsia 2008;49(10):1723–32.
   PubMed Web of Science ®Google Scholar
• Chen JW, Wasterlain CG. Status epilepticus: pathophysiology and management in adults. Lancet Neurol 2006;5(3):246–256.
   PubMed Web of Science ®Google Scholar
• Dinargl U, Iadecola C, Moskowitz M. Pathobiology of ischemic stroke: an integrated view. Trends Neurosci 1999;22:391–7.
   PubMed Web of Science ®Google Scholar
• Merelli A, Caltana L, Lazarowski A, Brusco A. Experimental evidence of the potential use of erythropoietin by intranasal administration as a neuroprotective agent in cerebral hypoxia. Drug Metab Drug Interact 2011;26(2):65–69.
   PubMedGoogle Scholar
• Bauer B, Hartz AM, Pekcec A, et al. Seizure-induced up-regulation of p-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling. Mol Pharmacool 2008;73:1444–1453.
   PubMed Web of Science ®Google Scholar
• Robey RW, Lazarowski A, Bates SE. P-glycoprotein—a clinical target in drug-refractory Epilepsy? Mol Pharmacol 2008;73:1343–1346.
   PubMed Web of Science ®Google Scholar
• Auzmendi JA, Orozco-Suárez S, Bañuelos-Cabrera I, et al. P-glycoprotein contributes to cell membrane depolarization of hippocampus and neocortex in a model of repetitive seizures induced by pentylenetetrazole in rats. Curr Pharm Des 2013;19(38):6732–8.
   PubMed Web of Science ®Google Scholar
• Bartesaghi S, Marinovich M, Corsini E, et al. Erythropoietin: a novel neuroprotective cytokine. Neurotoxicology 2005;26:923–8.
   PubMed Web of Science ®Google Scholar
• Sirén AL1, Fratelli M, Brines M, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A 2001;98:4044–9.
   PubMed Web of Science ®Google Scholar
• Wang L1, Zhang ZG, Zhang RL, et al. Matrix metalloproteinase 2 (MMP2) and MMP9 secreted by erythropoietin-activated endothelial cells promote neural progenitor cell migration. J Neurosci 2006;26:5996–6003.
   PubMed Web of Science ®Google Scholar
• Ransome MI, Turnley AM. Systemically delivered Erythropoietin transiently enhances adult hippocampal neurogenesis. J Neurochem 2007;102:1953–65.
   PubMed Web of Science ®Google Scholar
• Lu D, Mahmood A, Qu C, et al. Erythropoietin enhances neurogenesis and restores spatial memory in rats after traumatic brain injury. J Neurotrauma 2005;22:1011–7.
   PubMed Web of Science ®Google Scholar
• Zhang L, Chopp M, Zhang RL, et al. Erythropoietin amplifies stroke-induced oligodendrogenesis in the rat. PLoS One. 2010;5(6):e11016.
   PubMed Web of Science ®Google Scholar
• Henke M1, Laszig R, Rübe C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255–60.
   PubMed Web of Science ®Google Scholar
• Bohlius J, Wilson J, Seidenfeld J, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2006;3:CD003407.
   PubMedGoogle Scholar
• Genzis K and Islek I. Does erythropoietin cause epilepsy? Nephron 1996, 73, 320–321.
   PubMedGoogle Scholar
• Shimoda N, Maitani Y, Machida Y, Nagai T. Effects of dose, pH and osmolarity on intranasal absorption of recombinant human erythropoietin in rats. Biol Pharm Bull 1995;18:734–9.
   PubMed Web of Science ®Google Scholar
• Merelli A, Caltana L, Girimonti P, et al. Recovery of motor spontaneous activity after intranasal delivery of human recombinant erythropoietin in a focal brain hypoxia model induced by CoCl2 in rats. Neurotox Res 2011;20:182–92.
   PubMed Web of Science ®Google Scholar
• Genc S, Zadeoglulari Z, Gulfem Oner M, et al. Intranasal erythropoietin therapy in nervous system disorders. Expert Opin Drug Deliv 2011;8(1):19–32.
   PubMed Web of Science ®Google Scholar
• Dhuria SV, Hanson LR, Frey WH II. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sc 2010;99:1654–73.
   PubMed Web of Science ®Google Scholar
• Assaraf MI, Diaz Z, Liberman A, et al. Brain erythropoietin receptor expression in Alzheimer disease and mild cognitive impairment. J Neuropathol Exp Neurol 2007;66:389–398.
   PubMed Web of Science ®Google Scholar
• Lee ST, Chu K, Park JE, et al. Erythropoietin improves memory function with reducing endothelial dysfunction and amyloid-beta burden in Alzheimer's disease models. J Neurochem 2012;120(1):115–24.
   PubMed Web of Science ®Google Scholar
• Reger MA, Watson GS, Green PS, et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 2008;70:440–8.
   PubMed Web of Science ®Google Scholar
• Kang YJ, Digicaylioglu M, Russo R, et al. Erythropoietin plus insulin-like growth factor-I protects against neuronal damage in a murine model of human immunodeficiency virus-associated neurocognitive disorders. Ann Neurol 2010;68(3):342–52.
   PubMed Web of Science ®Google Scholar
• Maurice T, Mustafa MH, Desrumaux C, et al. Intranasal formulation of erythropoietin (EPO) showed potent protective activity against amyloid toxicity in the Ab25–35 non-transgenic mouse model of Alzheimer's disease. J Psychopharmacol 2013;27(11):1044–57.
   PubMed Web of Science ®Google Scholar
• Sun Y, Zhou C, Polk P, et al. Mechanisms of erythropoietin-induced brain protection in neonatal hypoxia-ischemia rat model. J Cereb Blood Flow Metab 2004;24:259–270.
   PubMed Web of Science ®Google Scholar
• Czornyj L. Encephalopathy in children infected by vertically transmitted human immunodeficiency virus. Rev Neurol. 2006;30,42(12):743–753.
   Google Scholar
• Mollacea V, Nottetb H, Clayettec P, et al. Oxidative stress and neuroAIDS: triggers, modulators and novel antioxidants. Trends in Neurosci 2001;24(7):411–416.
   PubMed Web of Science ®Google Scholar
• Freeman LR, Keller JN. Oxidative stress and cerebral endothelial cells: regulation of the blood–brain-barrier and antioxidant based interventions. Biochimica et Biophysica Acta 2012;1822:822–829.
   PubMed Web of Science ®Google Scholar
• Jelkmann W. Effects of erythropoietin on brain function. Curr Pharm Biotechnol 2005;6:65–79.
   PubMed Web of Science ®Google Scholar